Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update

BACKGROUND: As the international community dealt with the ongoing COVID-19 pandemic, important progress continued to be made in the development of new drug-based therapies for the neurodegenerative condition of Parkinson’s disease (PD) in 2021. This progress included both “symptomatic treatments” (S...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarthing, Kevin, Rafaloff, Gary, Baptista, Marco, Mursaleen, Leah, Fuest, Rosie, Wyse, Richard K., Stott, Simon R.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Clinical Trial Highlights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198738/
https://www.ncbi.nlm.nih.gov/pubmed/35527571
http://dx.doi.org/10.3233/JPD-229002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198738/
https://www.ncbi.nlm.nih.gov/pubmed/35527571
http://dx.doi.org/10.3233/JPD-229002

Ejemplares similares